Loading…
← CockpitCompetitor Analysis › 603983.SS Guangdong Marubi Biotechnology Co., Ltd. Class AOpen in the cockpit ↗

Guangdong Marubi Biotechnology Co., Ltd. Class A603983.SSCompetitor analysis, valuation and peers

China · CNY·Consumer Staples›Household/Personal Care

Chinese cosmetics company known for eye-care and anti-aging skincare products under the Marubi brand.

≈ A Chinese anti-aging/eye-care skincare brandMomentum leader 91
Mkt cap
$1.62B
US dollars, full cap
Free float
19%
of shares outstanding
$/day
$13.7M
20-day average traded
Fwd P/E
45.5×
forward earnings
ROIC−WACC
-3.7 pp
WACC 7.6%
Hurdle
n/a
no reverse DCF
Next earnings
159 days
26 Apr 2027
Close · CNYCN¥27.15
1D-1.2%
1W+12.5%
1M+4.7%
3M-7.5%
6M+9.3%
YTD-18.1%
1Y-18.5%
ATR %5.3%
52w lowhigh24.6% off high

What Guangdong Marubi Biotechnology does

Chinese cosmetics company known for eye-care and anti-aging skincare products under the Marubi brand.

Sells its skincare through online platforms and offline counters, with eye cream the product that built the brand and newer brands added to widen the range. It is founder-controlled.

In one line: A Chinese anti-aging/eye-care skincare brand.

Products and services

  • Eye-care skincare products
  • Anti-aging skincare
  • Makeup/other cosmetics

Customers

  • Online/retail consumers

Where it sits in the supply chain

  • Consumer staples
  • Personal care/cosmetics
  • Anti-aging/eye-care skincare

What could go right

  • Anti-aging skincare demand growth

What could go wrong

  • Intense domestic cosmetics competition
  • Marketing cost intensity

Moat: narrow (brand). Recognized eye-care skincare niche brand versus larger diversified beauty competitors.

Headquarters: Guangzhou, China · Employees: 1,380

Named competitors

Guangdong Marubi Biotechnology at a glance

Size Guangdong Marubi Biotechnology (603983.SS) is a China Consumer Staples company (Household/Personal Care) with a market value of $1.62B, the 1411th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥27.15 on 18 Nov 2026.

Performance Over six months the shares gained 9.3%, against +3.4% for the median peer and -20.0% for the China market (cap-weighted) — 10th highest of 21 in its peer set.

Growth Revenue fell 6.5% over the last twelve months (peer median +7.6%); the operating margin is 1.8% (peer median 9.9%).

Valuation It trades at 45.5× forward earnings against a peer median of 18.9× (2nd most expensive of 21).

Capital Return on invested capital runs 3.7 points below its cost of capital (7.6% WACC).

Next results Next results expected around 26 Apr 2027 (exchange calendar; dates can move).

Relative performance

10012014021 May 202621 Aug 202618 Nov 2026603983.SS 110Peer median 107
Six months, rebased to 100: Guangdong Marubi Biotechnology against the median of its 20 peers (local-currency closes).

Guangdong Marubi Biotechnology financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥3.24BCN¥3.44BCN¥2.95BCN¥2.21BCN¥1.71B
Revenue growth—+17%+34%+29%—
Gross profitCN¥2.41BCN¥2.51BCN¥2.16BCN¥1.55BCN¥1.15B
EBITDAn/aCN¥294MCN¥369MCN¥201MCN¥175M
Net incomeCN¥141MCN¥247MCN¥342MCN¥259MCN¥174M
Free cash flow-CN¥62.3MCN¥72.4M-CN¥6.50MCN¥115M-CN¥57.0M
Capital expenditureCN¥162MCN¥205MCN¥321MCN¥260MCN¥114M
Total debtCN¥457MCN¥398MCN¥794MCN¥255MCN¥285M

Quarterly statements and history in the cockpit →

Guangdong Marubi Biotechnology competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-20%-10%0%+10%6003150027903009573013717956ICOSENREMAMILTD003006EPC49271618906993492226982145483650PGHH2367192820603983.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Guangdong Marubi Biotechnology is the large dot.

Fundamentals: revenue growth against valuation

-10%0%+10%+20%+30%20×40×6003150027903009573013717956ICOSENREMAMILTD003006EPC49271618906993492226982145483650PGHH2367192820603983.SSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Guangdong Marubi Biotechnology is the large dot.

Guangdong Marubi Biotechnology competitors and peer comparison

Head to head with its named competitors (603983.SS vs 603605.SS vs 300957.SZ)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Guangdong Marubi Biotechnology 603983.SS$1.62B+9%-6%2%45.5×n/a
Proya Cosmetics 603605.SS$2.87B-13%+2%13%10.9×-5.3%
Yunnan Botanee Bio-Technology 300957.SZ$1.69B-33%+7%9%19.1×2.6%

How Guangdong Marubi Biotechnology compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Guangdong Marubi Biotechnology against its 20 peers (data as of 18 Nov 2026)
Measure603983.SSPeer medianRank in peer set
1-month return+4.7%+1.1%9th highest of 21
6-month return+9.3%+3.4%10th highest of 21
Distance from 52-week high-24.6%-24.5%11th highest of 21
Revenue growth (TTM)-6.5%+7.6%3rd lowest of 21
Operating margin1.8%9.9%2nd lowest of 21
Forward P/E45.5×18.9×2nd most expensive of 21
ROIC minus cost of capital-3.7 pp+6.2 pp3rd lowest of 20

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Guangdong Marubi Biotechnology 603983.SSChina$1.62B+9%-6%2%45.5×n/an/a
Shanghai Jahwa United 600315.SSChina$1.61B-15%+9%2%15.4×15.3%-2.1%
AMOREPACIFIC 002790.KSSouth Korea$1.61B+2%+9%9%8.5×-5.7%-1.3%
Yunnan Botanee Bio-Technology 300957.SZChina$1.69B-33%+7%9%19.1×2.6%+15.3%
Harbin Fuerjia Technology 301371.SZChina$1.51B-39%+28%20%21.4×7.5%+3.6%
Pigeon 7956.TJapan$1.76B+26%+8%13%27.9×-2.4%+1.9%
Intercos ICOS.MIItaly$1.43B+12%-5%9%18.9×4.3%+11.5%
Energizer ENRUnited States$1.94B+71%0%17%9.1×-5.1%-0.5%
Emami EMAMILTD.NSIndia$1.94B-5%+13%20%23.4×21.5%+5.6%
Chongqing Baiya Sanitary Products 003006.SZChina$1.35B+27%0%3%37.3×28.8%+22.8%
Edgewell Personal Care EPCUnited States$1.30B+67%-10%7%14.2×n/an/a
Pola Orbis 4927.TJapan$2.04B+15%+1%11%30.6×-2.0%-0.7%
Kolmar Korea 161890.KSSouth Korea$2.05B+14%+16%10%14.3×-1.6%+15.5%
Blue Moon 6993.HKHong Kong$2.07B-4%-2%-2%103.3×n/an/a
KOSE 4922.TJapan$2.16B+16%+4%5%29.9×n/an/a
Softcare 2698.HKHong Kong$2.20B+5%+25%25%14.4×9.1%+20.9%
Shanghai Chicmax Cosmetics 2145.HKHong Kong$1.17B-42%+23%8%14.4×-6.1%+21.2%
d'Alba Global 483650.KSSouth Korea$1.13B-55%+49%22%12.0×-6.6%+53.0%
Procter & Gamble Hygiene & Health Care PGHH.NSIndia$2.37B-30%-2%24%27.0×21.2%+7.4%
Giant Biogene 2367.HKHong Kong$2.47B-32%-10%32%8.6×-10.7%+34.9%
Cosmax 192820.KSSouth Korea$2.51B+53%+25%8%18.8×n/an/a

Questions

Who are Guangdong Marubi Biotechnology's main competitors?
Named competitors: Proya Cosmetics (603605.SS), Yunnan Botanee (300957.SZ). The cockpit's measured peer set (industry) also includes Shanghai Jahwa United (600315.SS), AMOREPACIFIC (002790.KS), Yunnan Botanee Bio-Technology (300957.SZ), Harbin Fuerjia Technology (301371.SZ), Pigeon (7956.T), Intercos (ICOS.MI).
Is Guangdong Marubi Biotechnology expensive compared with its peers?
On forward p/e it trades at 45.5× against a peer median of 18.9×, 2nd most expensive of 21 in its peer set.
How has Guangdong Marubi Biotechnology stock performed?
Over six months to 18 Nov 2026 the shares returned +9.3% against +3.4% for the median peer; over one year -18.5%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.